 The study will include up to two hundred 200 patients, up to 10 centers, and provide a prospective evaluation of the InterFuse T andor InterFuse S Interbody Fusion System. Primary endpoints will be assessed at twelve months post-surgery. All patients enrolled in the study will be followed for at least 24 months. 